- Introduction to HIV and AIDS
- The immune system and HIV
- Medical monitoring
- Accessing medical care
- Ways of attacking HIV
- Preventing HIV infection
- Starting HIV treatment
- Side-effects
- Adherence
- Drug resistance
- Drug interactions and pharmacokinetics
- Changing HIV treatment
- Interrupting HIV treatment
- HIV treatment during pregnancy
- HIV treatment in children
- Genetics and HIV treatment
- Treatment guidelines
- Preventing infections
- Antiretroviral therapy in resource-limited settings
- Drugs used by people with HIV
- Symptoms and illnesses
- Alternative & complementary therapies
Interrupting HIV treatment
People who have been taking anti-HIV treatment and have long-term infection may wish to take breaks from treatment for several reasons. These include the relief of side-effects, to stimulate the return of drug-sensitive virus, to have a break from taking treatment every day or to re-stimulate the immune system by allowing viral loads to rise. Structured treatment interruptions are breaks from antiretroviral therapy that may be open-ended or be of pre-determined duration. Recent studies have also been looking at guiding intermittent therapy using CD4 cell count.
Despite the predicted benefits of HIV treatment interruptions, there are a number of risks involved in stopping treatment, some of which can be serious. In addition to rises in viral load and falls in CD4 cell count, recent studies have shown that some treatment interruption strategies put patients at a high risk of disease progression or death. Consequently, they cannot be recommended outside the setting of clinical trials until the results of further research are published.
Patients may also wish to interrupt treatment for other reasons, including having surgery or travelling to regions where they cannot take their anti-HIV medication. Patients are advised to consult their HIV doctor before deciding to stop treatment, to agree upon the safest strategy.
latest aidsmap news
- US Health Department identifies further 18 effective HIV prevention programmes
- More African people acquiring HIV in the UK than previously thought
- HIV prevalence may decline because the most vulnerable are infected and die first
- Lack of perceived need for HIV treatment associated with poor adherence
- TB doesn't always increase HIV viral load
- New 75mg darunavir tablet approved by FDA for use by HIV-positive children
- Thyroid checks recommended for people with HIV
- Knighthood for head of UK HIV charity
- Gay men often not accessing PEP despite risk of HIV exposure
- Inflammatory cytokines may contribute to endothelial dysfunction in people with untreated HIV
